National Cancer Institute CRADA
Executive Summary
NCI seeks pharmaceutical company partner to develop LMB-7 recombinant immunotoxin for certain cancers. In an April 14 Federal Register notice announcing the availability of the Cooperative Research and Development Agreement, NCI states that LMB-7 "has been shown to cause the complete regression of human cancers growing in immunodeficient mice." Questions concerning the LMB-7 CRADA should be directed to Ira Pastan, MD, NCI Division of Cancer Biology Diagnosis and Centers, (301) 496-4797.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth